UA79480C2 - Disorazol containing drug for treating benign and malignant tumors - Google Patents

Disorazol containing drug for treating benign and malignant tumors Download PDF

Info

Publication number: UA79480C2
Authority: UA; Ukraine
Prior art keywords: alkyl; general formula; disorazole; cancer; treatment
Prior art date: 2002-08-24

Application number

UAA200501355A

Other languages

English (en)

Ukrainian (uk)

Inventor

Herbert Irschik

Rolf Jansen

Florenz Sasse

Silke Baasner

Peter Schmidt

Eckhard Guenther

Original Assignee

Zentaris Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-24

Filing date

2003-08-22

Publication date

2007-06-25

2003-08-22 Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh

2007-06-25 Publication of UA79480C2 publication Critical patent/UA79480C2/uk

Links

239000003814 drug Substances 0.000 title claims abstract description 22
201000011510 cancer Diseases 0.000 title claims description 12
229940079593 drug Drugs 0.000 title claims description 9
229930193554 Disorazol Natural products 0.000 title description 20
229930187817 disorazole Natural products 0.000 claims abstract description 37
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
201000010099 disease Diseases 0.000 claims abstract description 11
210000004027 cell Anatomy 0.000 claims description 37
150000001875 compounds Chemical class 0.000 claims description 32
206010028980 Neoplasm Diseases 0.000 claims description 24
-1 alkyl radical Chemical group 0.000 claims description 19
239000000126 substance Substances 0.000 claims description 14
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
229910052739 hydrogen Inorganic materials 0.000 claims description 11
239000001257 hydrogen Substances 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 11
229910052760 oxygen Inorganic materials 0.000 claims description 11
239000001301 oxygen Substances 0.000 claims description 11
230000021603 oncosis Effects 0.000 claims description 10
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 9
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
241001465754 Metazoa Species 0.000 claims description 8
230000003211 malignant effect Effects 0.000 claims description 8
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
DUKYFBNEOVBQQG-UHFFFAOYSA-N disorazole E1 Natural products O=C1OC(C(C)(C)C(O)C=CC)CC=CC2OC2C=CC(OC)CC(OC=2)=NC=2C(=O)OC(C(C)(C)C(O)C=CC)CC=CC2OC2C=CC=CC2=NC1=CO2 DUKYFBNEOVBQQG-UHFFFAOYSA-N 0.000 claims description 7
229910052717 sulfur Inorganic materials 0.000 claims description 7
239000011593 sulfur Substances 0.000 claims description 7
231100000433 cytotoxic Toxicity 0.000 claims description 6
230000001472 cytotoxic effect Effects 0.000 claims description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
230000002062 proliferating effect Effects 0.000 claims description 6
239000000243 solution Substances 0.000 claims description 6
125000001424 substituent group Chemical group 0.000 claims description 6
125000004429 atom Chemical group 0.000 claims description 5
125000005842 heteroatom Chemical group 0.000 claims description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
239000000725 suspension Substances 0.000 claims description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
229960004679 doxorubicin Drugs 0.000 claims description 4
239000007943 implant Substances 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 4
239000003112 inhibitor Substances 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
230000035755 proliferation Effects 0.000 claims description 4
230000019491 signal transduction Effects 0.000 claims description 4
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 3
206010006187 Breast cancer Diseases 0.000 claims description 3
208000026310 Breast neoplasm Diseases 0.000 claims description 3
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
206010061218 Inflammation Diseases 0.000 claims description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
206010033128 Ovarian cancer Diseases 0.000 claims description 3
229930012538 Paclitaxel Natural products 0.000 claims description 3
206010060862 Prostate cancer Diseases 0.000 claims description 3
150000005840 aryl radicals Chemical group 0.000 claims description 3
208000006673 asthma Diseases 0.000 claims description 3
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 3
229960004562 carboplatin Drugs 0.000 claims description 3
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
229960004316 cisplatin Drugs 0.000 claims description 3
208000029742 colonic neoplasm Diseases 0.000 claims description 3
229960004397 cyclophosphamide Drugs 0.000 claims description 3
125000001153 fluoro group Chemical group F* 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
229960001101 ifosfamide Drugs 0.000 claims description 3
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 3
208000027866 inflammatory disease Diseases 0.000 claims description 3
230000004054 inflammatory process Effects 0.000 claims description 3
229960000485 methotrexate Drugs 0.000 claims description 3
239000002674 ointment Substances 0.000 claims description 3
229960001592 paclitaxel Drugs 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
229960004528 vincristine Drugs 0.000 claims description 3
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 3
229960004355 vindesine Drugs 0.000 claims description 3
208000003174 Brain Neoplasms Diseases 0.000 claims description 2
206010006895 Cachexia Diseases 0.000 claims description 2
206010009944 Colon cancer Diseases 0.000 claims description 2
206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
208000011231 Crohn disease Diseases 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
206010020649 Hyperkeratosis Diseases 0.000 claims description 2
208000001126 Keratosis Diseases 0.000 claims description 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
201000004681 Psoriasis Diseases 0.000 claims description 2
206010037660 Pyrexia Diseases 0.000 claims description 2
206010039085 Rhinitis allergic Diseases 0.000 claims description 2
208000000453 Skin Neoplasms Diseases 0.000 claims description 2
208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
201000010105 allergic rhinitis Diseases 0.000 claims description 2
206010003246 arthritis Diseases 0.000 claims description 2
208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
229960003668 docetaxel Drugs 0.000 claims description 2
239000000839 emulsion Substances 0.000 claims description 2
210000003979 eosinophil Anatomy 0.000 claims description 2
239000000945 filler Substances 0.000 claims description 2
239000006260 foam Substances 0.000 claims description 2
125000000623 heterocyclic group Chemical group 0.000 claims description 2
230000002519 immonomodulatory effect Effects 0.000 claims description 2
239000002955 immunomodulating agent Substances 0.000 claims description 2
229940121354 immunomodulator Drugs 0.000 claims description 2
208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 2
201000005202 lung cancer Diseases 0.000 claims description 2
208000020816 lung neoplasm Diseases 0.000 claims description 2
201000004792 malaria Diseases 0.000 claims description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
230000001404 mediated effect Effects 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
201000002528 pancreatic cancer Diseases 0.000 claims description 2
208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
239000006072 paste Substances 0.000 claims description 2
201000000849 skin cancer Diseases 0.000 claims description 2
229940126601 medicinal product Drugs 0.000 claims 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
208000030507 AIDS Diseases 0.000 claims 1
206010003210 Arteriosclerosis Diseases 0.000 claims 1
208000035473 Communicable disease Diseases 0.000 claims 1
206010012434 Dermatitis allergic Diseases 0.000 claims 1
208000008839 Kidney Neoplasms Diseases 0.000 claims 1
206010038389 Renal cancer Diseases 0.000 claims 1
208000026935 allergic disease Diseases 0.000 claims 1
239000002246 antineoplastic agent Substances 0.000 claims 1
208000011775 arteriosclerosis disease Diseases 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
230000002757 inflammatory effect Effects 0.000 claims 1
201000010982 kidney cancer Diseases 0.000 claims 1
201000007270 liver cancer Diseases 0.000 claims 1
208000014018 liver neoplasm Diseases 0.000 claims 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
229910052698 phosphorus Inorganic materials 0.000 claims 1
208000023504 respiratory system disease Diseases 0.000 claims 1
230000001173 tumoral effect Effects 0.000 abstract 2
201000009030 Carcinoma Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
238000002347 injection Methods 0.000 description 15
239000007924 injection Substances 0.000 description 15
230000000694 effects Effects 0.000 description 12
239000000203 mixture Substances 0.000 description 12
238000012360 testing method Methods 0.000 description 11
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
239000002904 solvent Substances 0.000 description 9
230000022131 cell cycle Effects 0.000 description 8
230000001028 anti-proliverative effect Effects 0.000 description 7
ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
238000001802 infusion Methods 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 5
241000282412 Homo Species 0.000 description 4
230000034994 death Effects 0.000 description 4
231100000517 death Toxicity 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
230000014616 translation Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
102000004243 Tubulin Human genes 0.000 description 3
108090000704 Tubulin Proteins 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
238000011161 development Methods 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
239000005445 natural material Substances 0.000 description 3
238000006116 polymerization reaction Methods 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
210000001541 thymus gland Anatomy 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 2
MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
210000000683 abdominal cavity Anatomy 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
125000004448 alkyl carbonyl group Chemical group 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 2
230000032823 cell division Effects 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
201000005296 lung carcinoma Diseases 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
241000408923 Appia Species 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
206010007269 Carcinogenicity Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
FRFRWOXVYJSPCG-OMCKPOKKSA-N Disorazol A Natural products O(C)[C@@H]1/C=C/C=C\C=C/C[C@@H](C([C@@H](O)/C=C/C)(C)C)OC(=O)c2nc(oc2)/C=C\C=C\[C@@H]2O[C@@H]2/C=C\C[C@@H](C([C@@H](O)/C=C/C)(C)C)OC(=O)c2nc(oc2)C1 FRFRWOXVYJSPCG-OMCKPOKKSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010014950 Eosinophilia Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
208000029464 Pulmonary infiltrates Diseases 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
101100001207 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ags1 gene Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
230000009471 action Effects 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
210000002821 alveolar epithelial cell Anatomy 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
208000016063 arterial thoracic outlet syndrome Diseases 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000036815 beta tubulin Diseases 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
208000019664 bone resorption disease Diseases 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
231100000260 carcinogenicity Toxicity 0.000 description 1
230000007670 carcinogenicity Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
201000010897 colon adenocarcinoma Diseases 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
FRFRWOXVYJSPCG-UHFFFAOYSA-N disorazole A1 Natural products O=C1OC(C(C)(C)C(O)C=CC)CC=CC2OC2C=CC=CC(OC=2)=NC=2C(=O)OC(C(C)(C)C(O)C=CC)CC=CC=CC=CC(OC)CC2=NC1=CO2 FRFRWOXVYJSPCG-UHFFFAOYSA-N 0.000 description 1
FRFRWOXVYJSPCG-YEYPPUHMSA-N disorazole a1 Chemical compound C(/[C@@H]1O[C@@H]1\C=C/C[C@H](OC1=O)C(C)(C)[C@@H](O)\C=C\C)=C\C=C/C(OC=2)=NC=2C(=O)O[C@H](C(C)(C)[C@@H](O)\C=C\C)C\C=C/C=C\C=C\[C@H](OC)CC2=NC1=CO2 FRFRWOXVYJSPCG-YEYPPUHMSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000001516 effect on protein Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
201000009580 eosinophilic pneumonia Diseases 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
230000012010 growth Effects 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
210000003128 head Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000016507 interphase Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
230000007886 mutagenicity Effects 0.000 description 1
231100000299 mutagenicity Toxicity 0.000 description 1
231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000036438 mutation frequency Effects 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
201000006588 ovary adenocarcinoma Diseases 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
238000012856 packing Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
201000009732 pulmonary eosinophilia Diseases 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
230000005855 radiation Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003744 tubulin modulator Substances 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)

UAA200501355A 2002-08-24 2003-08-22 Disorazol containing drug for treating benign and malignant tumors UA79480C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40559402P	2002-08-24	2002-08-24
PCT/EP2003/009329 WO2004024149A1 (de)	2002-08-24	2003-08-22	Arzneimittel enthaltend disorale und ihre derivate und deren anwendung zur behandlung gutartiger und bosärtiger tumorerkrankungen

Publications (1)

Publication Number	Publication Date
UA79480C2 true UA79480C2 (en)	2007-06-25

Family

ID=31993935

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200501355A UA79480C2 (en)	2002-08-24	2003-08-22	Disorazol containing drug for treating benign and malignant tumors

Country Status (20)

Country	Link
US (2)	US20040106662A1 (pl)
EP (1)	EP1536789A1 (pl)
JP (1)	JP2006500398A (pl)
KR (1)	KR20050038632A (pl)
CN (1)	CN1678310A (pl)
AR (1)	AR042617A1 (pl)
AU (1)	AU2003296872B2 (pl)
BR (1)	BR0313789A (pl)
CA (1)	CA2438001A1 (pl)
HR (1)	HRP20050277A2 (pl)
IL (1)	IL166588A0 (pl)
MX (1)	MXPA05002157A (pl)
NO (1)	NO20051444L (pl)
NZ (1)	NZ538926A (pl)
PL (1)	PL376407A1 (pl)
RU (1)	RU2322236C2 (pl)
TW (1)	TW200404537A (pl)
UA (1)	UA79480C2 (pl)
WO (1)	WO2004024149A1 (pl)
ZA (1)	ZA200501196B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0716190A2 (pt) *	2006-09-06	2013-11-12	Aeterna Zentaris Gmbh	Conjugados de disorazóis e seus derivados com móleculas de ligação celular, derivados de disorazol, processos para fabricação e uso dos mesmos
EP1900742A1 (en)	2006-09-07	2008-03-19	AEterna Zentaris GmbH	Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
HRP20160631T1 (hr) *	2006-09-06	2016-07-15	Æterna Zentaris Gmbh	Konjugati disorazola i njihovi derivati sa staničnovezajućim molekulama, novi derivati disorazola, postupci njihove pripreme i njihove uporabe
WO2018237178A1 (en) *	2017-06-22	2018-12-27	William Marsh Rice University	SYNTHESIS OF DISORAZOLES AND THEIR ANALOGUES AS POWERFUL ANTICANCER AGENTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19605024A1 (de) *	1996-01-31	1997-08-07	Schering Ag	Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
WO2003011832A1 (en) *	2001-07-31	2003-02-13	Wayne State University	Quinoline derivatives and use thereof as antitumor agents
UA79293C2 (en) *	2002-07-03	2007-06-11	Univ Wayne State	4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents
AU2003298864A1 (en) *	2002-12-06	2004-06-30	Kosan Biosciences, Inc.	Disorazole polyketide synthase encoding polynucleotides

2003
- 2003-08-22 CA CA002438001A patent/CA2438001A1/en not_active Abandoned
- 2003-08-22 RU RU2005108570/15A patent/RU2322236C2/ru not_active IP Right Cessation
- 2003-08-22 WO PCT/EP2003/009329 patent/WO2004024149A1/de not_active Ceased
- 2003-08-22 NZ NZ538926A patent/NZ538926A/xx unknown
- 2003-08-22 JP JP2004535140A patent/JP2006500398A/ja not_active Withdrawn
- 2003-08-22 EP EP03794920A patent/EP1536789A1/de not_active Withdrawn
- 2003-08-22 TW TW092123217A patent/TW200404537A/zh unknown
- 2003-08-22 BR BR0313789-9A patent/BR0313789A/pt not_active IP Right Cessation
- 2003-08-22 MX MXPA05002157A patent/MXPA05002157A/es active IP Right Grant
- 2003-08-22 HR HR20050277A patent/HRP20050277A2/hr not_active Application Discontinuation
- 2003-08-22 AR ARP030103050A patent/AR042617A1/es unknown
- 2003-08-22 AU AU2003296872A patent/AU2003296872B2/en not_active Ceased
- 2003-08-22 US US10/646,904 patent/US20040106662A1/en not_active Abandoned
- 2003-08-22 UA UAA200501355A patent/UA79480C2/uk unknown
- 2003-08-22 CN CNA038200937A patent/CN1678310A/zh active Pending
- 2003-08-22 PL PL03376407A patent/PL376407A1/pl not_active Application Discontinuation
- 2003-08-22 KR KR1020057003109A patent/KR20050038632A/ko not_active Ceased
2005
- 2005-01-31 IL IL16658805A patent/IL166588A0/xx unknown
- 2005-02-10 ZA ZA2005/01196A patent/ZA200501196B/en unknown
- 2005-03-18 NO NO20051444A patent/NO20051444L/no not_active Application Discontinuation
2009
- 2009-04-07 US US12/263,981 patent/US20090311264A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ZA200501196B (en)	2005-10-26
JP2006500398A (ja)	2006-01-05
PL376407A1 (pl)	2005-12-27
KR20050038632A (ko)	2005-04-27
IL166588A0 (en)	2006-01-15
HRP20050277A2 (en)	2005-04-30
TW200404537A (en)	2004-04-01
US20090311264A1 (en)	2009-12-17
NO20051444L (no)	2005-05-19
RU2005108570A (ru)	2005-08-27
MXPA05002157A (es)	2005-05-23
RU2322236C2 (ru)	2008-04-20
BR0313789A (pt)	2005-07-05
US20040106662A1 (en)	2004-06-03
NZ538926A (en)	2006-03-31
EP1536789A1 (de)	2005-06-08
AU2003296872B2 (en)	2008-02-14
AU2003296872A1 (en)	2004-04-30
CN1678310A (zh)	2005-10-05
CA2438001A1 (en)	2004-02-24
AR042617A1 (es)	2005-06-29
WO2004024149A1 (de)	2004-03-25

Publication	Publication Date	Title
EP3395820B1 (en)	2019-05-15	Antitumoral compounds
HK1255941A1 (en)	2019-09-06	Antitumoral compounds
HK1255938A1 (en)	2019-09-06	Antitumoral compounds
JP2024028794A (ja)	2024-03-05	オキサチアジン様化合物を作製する方法
KR20210070978A (ko)	2021-06-15	화합물 및 이의 용도
AU2006216031A1 (en)	2006-08-24	Anti-tumor agent
US20090311264A1 (en)	2009-12-17	Use of Disorazoles and Their Derivatives for the Treatment of Benign and Malignant Oncoses
ES2749053T3 (es)	2020-03-18	Polimixinas de baja sustitución y sus composiciones
JP2013525290A5 (pl)	2014-04-24
EP3984993A1 (en)	2022-04-20	Use of aminothiol compounds as cerebral nerve or heart protective agent
CN116270657B (zh)	2023-08-18	一种预防和/或治疗胃肠道疾病的药物组合物及其用途
WO2018058863A1 (zh)	2018-04-05	聚醚类化合物用途
CN106924225A (zh)	2017-07-07	厚朴酚在制备抗肿瘤药物增敏剂中的应用
JPS60222494A (ja)	1985-11-07	オキサザホスホリン誘導体の塩及びその製法
JP2020070269A (ja)	2020-05-07	スガマデクス又はその薬理学的に許容される塩含有液剤及びその製造方法
CN104873493B (zh)	2017-10-10	2‑羟基泽兰内酯在制备抗肿瘤药物中的应用
CN110709079A (zh)	2020-01-17	包含1，2-萘醌衍生物化合物的实体癌或血液癌的预防或治疗用药物组合物
CN116850187A (zh)	2023-10-10	Hapalindole在制备抑制肝癌或乳腺癌的药物中的应用
CN118164978A (zh)	2024-06-11	二氢喹嗪酮羧酸类化合物及其作为trpv4通道抑制剂的应用
HK1081458A (en)	2006-05-19	Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases
CN106806373A (zh)	2017-06-09	雅姆皂苷元在制备抗肿瘤药物增敏剂中的应用
CN106890173A (zh)	2017-06-27	2-羟基泽兰内酯在制备抗肿瘤药物增敏剂中的应用
CN106924244A (zh)	2017-07-07	异甜菊醇内酰胺在制备抗肿瘤药物增敏剂中的应用